Differential exhaustion on cytokine release (DECREASE) by ERY974, a novel T-cell-redirecting antibody targeting glypican-3: A new type of T-cell exhaustion

被引：0
|
作者：
Hoshino, Mayumi [1 ]
Sano, Yuji [1 ]
Kinoshita, Yasuko [1 ]
Azuma, Yumiko [1 ]
Tsunenari, Toshiaki [1 ]
Kayukawa, Yoko [1 ]
Noguchi, Mizuho [1 ]
Ishiguro, Takahiro [1 ]
Kishishita, Shohei [1 ]
Sawada, Noriaki [1 ]
Endo, Mika [1 ]
Nezu, Junichi [1 ]
机构：
[1] Chugai Pharmaceut Co Ltd, Tokyo, Japan
来源：
CANCER RESEARCH | 2019年 / 79卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2019-2378
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2378
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Impact of regulatory T cells on cellular cytotoxicity induced by ERY974, a novel T cell-redirecting bispecific antibody targeting glypican-3
    Sonobe, Y.
    Miyazaki, Y.
    Sano, Y.
    Kinoshita, Y.
    Azuma, Y.
    Tsunenari, T.
    Ishiguro, T.
    Kishishita, S.
    Endo, M.
    Nezu, J.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E55 - E55
  • [2] Determination of starting dose of the T cell-redirecting bispecific antibody ERY974 targeting glypican-3 in first-in-human clinical trial
    Shun-ichiro Komatsu
    Yoko Kayukawa
    Yoko Miyazaki
    Akihisa Kaneko
    Hisashi Ikegami
    Takahiro Ishiguro
    Mikiko Nakamura
    Werner Frings
    Natsuki Ono
    Kiyoaki Sakata
    Toshihiko Fujii
    Shohei Kishishita
    Takehisa Kitazawa
    Mika Endo
    Yuji Sano
    Scientific Reports, 12
  • [3] Determination of starting dose of the T cell-redirecting bispecific antibody ERY974 targeting glypican-3 in first-in-human clinical trial
    Komatsu, Shun-ichiro
    Kayukawa, Yoko
    Miyazaki, Yoko
    Kaneko, Akihisa
    Ikegami, Hisashi
    Ishiguro, Takahiro
    Nakamura, Mikiko
    Frings, Werner
    Ono, Natsuki
    Sakata, Kiyoaki
    Fujii, Toshihiko
    Kishishita, Shohei
    Kitazawa, Takehisa
    Endo, Mika
    Sano, Yuji
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [4] ERY974, a novel T cell-redirecting bispecific antibody targeting glypican-3, shows antitumor activity in gastric cancer patient-derived xenograft models with varying glypican-3 expression
    Yumiko, Azuma
    Sano, Yuji
    Tsunenari, Toshiaki
    Kinoshita, Yasuko
    Miyazaki, Yoko
    Shinozuka, Junko
    Fujii, Etsuko
    Kato, Atsuhiko
    Ishiguro, Takahiro
    Kishishita, Shohei
    Nezu, Junichi
    Kawabe, Yoshiki
    Endo, Mika
    CANCER RESEARCH, 2018, 78 (13)
  • [5] Determination of the starting dose in the first-in-human clinical trial of ERY974, a novel T cell-redirecting bispecific antibody targeting glypican-3, from MABEL and NOAEL approaches
    Sano, Y.
    Komatsu, S. I.
    Frings, W.
    Kaneko, A.
    Takahiro, I.
    Kayukawa, Y.
    Ono, N.
    Sakata, K.
    Fujii, T.
    Miyazaki, Y.
    Kinoshita, Y.
    Azuma, Y.
    Tsunenari, T.
    Kishishita, S.
    Endo, M.
    Nezu, J.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E107 - E108
  • [6] Pharmacological Characterization of Anti-Glypican 3/CD3 Bispecific T Cell-Redirecting Antibody ERY974
    Kishishita, Shohei
    CANCER SCIENCE, 2018, 109 : 332 - 332
  • [7] Daily ascending dosing in cynomolgus monkeys to mitigate cytokine release syndrome induced by ERY22, surrogate for T-cell redirecting bispecific antibody ERY974 for cancer immunotherapy
    Iwata, Yoshika
    Sasaki, Masanori
    Harada, Asako
    Taketo, Junko
    Hara, Toshiko
    Akai, Sho
    Ishiguro, Takahiro
    Narita, Atsushi
    Kaneko, Akihisa
    Mishima, Masayuki
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 2019, 379
  • [8] Priming treatment with T-cell redirecting bispecific antibody ERY974 reduced cytokine induction without losing cytotoxic activity in vitro by changing the chromatin state in T cells
    Iwata, Yoshika
    Narushima, Yuta
    Harada, Asako
    Mishima, Masayuki
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 2022, 441
  • [9] Combining ERY974, a novel Tcell-redirecting bispecific antibody targeting glypican-3, with chemotherapy profoundly improved antitumor efficacy over its monotherapy in xenograft model
    Sano, Yuji
    Azuma, Yumiko
    Tsunenari, Toshiaki
    Kinoshita, Yasuko
    Kayukawa, Yoko
    Mutoh, Hironori
    Miyazaki, Yoko
    Ishiguro, Takahiro
    Kishishita, Shohei
    Kawabe, Yoshiki
    Endo, Mika
    CANCER RESEARCH, 2017, 77
  • [10] Preclinical PET imaging of bispecific antibody ERY974 targeting CD3 and glypican 3 reveals that tumor uptake correlates to T cell infiltrate
    Waaijer, Stijn J. H.
    Giesen, Danique
    Ishiguro, Takahiro
    Sano, Yuji
    Sugaya, Naofumi
    Schroder, Carolina P.
    de Vries, Elisabeth G. E.
    Lub-de Hooge, Marjolijn N.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (01)
12345